Inphena A

Inphena is a biotechnology company focused on developing a new class of precision oncology therapeutics that target the DNA replication machinery of cancer cells. The company's primary focus is on the inhibition of DNA polymerases, specifically targeting the replicative polymerases alpha, delta, and epsilon to induce synthetic lethality in tumors with specific genetic vulnerabilities. By exploiting the high replication stress inherent in many aggressive cancers, Inphena aims to create highly selective treatments that minimize damage to healthy tissues. Their lead programs are currently in the pre-clinical stage, with a focus on solid tumors and hematological malignancies that have failed standard-of-care therapies.